Genetically engineered dendritic cell-based cancer vaccines (Review)

  • Authors:
    • J. Bubenik
  • View Affiliations

  • Published online on: March 1, 2001     https://doi.org/10.3892/ijo.18.3.475
  • Pages: 475-478
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Dendritic cells (DCs) are the most potent professional antigen-presenting cells with exquisite capacity to interact with T cells and initiate their responses; the antigen-presenting capabilities of DCs make them attractive vehicles for the delivery of therapeutic cancer vaccines. The working hypothesis for utilization of DC-based cancer vaccines is that lack of efficient tumour antigen presentation on mature DCs, which is frequently observed in tumour-bearing individuals, can be bypassed by direct loading of DCs with oncoproteins in vitro, thus ensuring the transfer of immunostimulatory peptides on the respective antigen-presenting molecules. To enhance loading of DCs with oncoproteins in vitro and to increase the efficacy of the vaccines, a variety of genetic manipulations have been proposed and shown to be efficient in experimental tumour models. DCs were transfected either with polynucleotides, DNA or RNA, coding for tumour-associated antigens (TAAs), or with DNA encoding immunostimulatory cytokines and co-stimulatory molecules. The delivery of genes coding for antigenic epitopes or other molecules with a recombinant retrovirus, adenovirus, or poxvirus into dendritic cells has also been used for transduction and therapy. As an alternative method for TAA delivery into DCs, fusion of DCs with tumour cells has been utilized and the hybrid cell-based vaccines have been found to be highly therapeutically active, even in cancer patients. The purpose of this review is to summarize the approaches used for making and utilization of the genetically engineered DC-based cancer vaccines, to evaluate the therapeutic results obtained with the vaccines, and to discuss prospects and limitations of the vaccination.

Related Articles

Journal Cover

March 2001
Volume 18 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Bubenik J: Genetically engineered dendritic cell-based cancer vaccines (Review). Int J Oncol 18: 475-478, 2001.
APA
Bubenik, J. (2001). Genetically engineered dendritic cell-based cancer vaccines (Review). International Journal of Oncology, 18, 475-478. https://doi.org/10.3892/ijo.18.3.475
MLA
Bubenik, J."Genetically engineered dendritic cell-based cancer vaccines (Review)". International Journal of Oncology 18.3 (2001): 475-478.
Chicago
Bubenik, J."Genetically engineered dendritic cell-based cancer vaccines (Review)". International Journal of Oncology 18, no. 3 (2001): 475-478. https://doi.org/10.3892/ijo.18.3.475